Last reviewed · How we verify
NM6603
At a glance
| Generic name | NM6603 |
|---|---|
| Sponsor | NucMito Pharmaceuticals Co. Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety and Pharmacokinetics of NM6603 in Chinese Patients With Advanced Solid Tumors (PHASE1)
- A Phase 1 Study of NM6603 in Advanced Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NM6603 CI brief — competitive landscape report
- NM6603 updates RSS · CI watch RSS
- NucMito Pharmaceuticals Co. Ltd. portfolio CI